{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:21:31Z","timestamp":1791397291440,"version":"4.3.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7-8","license":[{"start":{"date-parts":[[2003,4,1]],"date-time":"2003-04-01T00:00:00Z","timestamp":1049155200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2003,4]]},"DOI":"10.1007\/bf03040321","type":"journal-article","created":{"date-parts":[[2009,5,12]],"date-time":"2009-05-12T17:49:58Z","timestamp":1242150598000},"page":"235-240","source":"Crossref","is-referenced-by-count":9,"title":["Anderson-Fabry disease in Austria","Morbus Fabry in \u00d6sterreich"],"prefix":"10.1007","volume":"115","author":[{"given":"Matthias","family":"Lorenz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Christina","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot","family":"P\u00fcsp\u00f6k-Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kotanko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Zodl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Kramar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Paschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Voigtl\u00e4nder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gere","family":"Sunder-Plassmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BF03040321_CR1","first-page":"2741","volume-title":"The metabolic and molecular bases of inherited disease","author":"RJ Desnick","year":"1995","unstructured":"Desnick RJ, Ioannou YA, Eng CM (1995) \u03b1-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS DV (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 2741\u20132784"},{"key":"BF03040321_CR2","first-page":"67","volume":"34","author":"A Colombi","year":"1967","unstructured":"Colombi A, Kostyal A, Bracher R, Gloor F, Mazzi R, Tholen H (1967) Angiokeratoma corporis diffusum \u2014 Fabry\u2019s disease. Helv Med Acta 34: 67\u201383","journal-title":"Helv Med Acta"},{"key":"BF03040321_CR3","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1023\/A:1012993305223","volume":"24","author":"C Whybra","year":"2001","unstructured":"Whybra C, Kampmann C, Willers I, Davies J, Winchester B, Kriegsmann J, Bruhl K, Gal A, Bunge S, Beck M (2001) Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 24: 715\u2013724","journal-title":"J Inherit Metab Dis"},{"key":"BF03040321_CR4","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/250651a0","volume":"250","author":"MF Lyon","year":"1974","unstructured":"Lyon MF (1974) Evolution of X-chromosome inactivation in mammals. Nature 250: 651\u2013653","journal-title":"Nature"},{"key":"BF03040321_CR5","first-page":"361","volume":"29","author":"HH Ropers","year":"1977","unstructured":"Ropers HH, Wienker TF, Grimm T, Schroetter K, Bender K (1977) Evidence for preferential X-chromosome inactivation in a family with Fabry disease. Am J Hum Genet 29: 361\u2013370","journal-title":"Am J Hum Genet"},{"key":"BF03040321_CR6","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1001\/archopht.1979.01020010327008","volume":"97","author":"NA Sher","year":"1979","unstructured":"Sher NA, Letson RD, Desnick RJ (1979) The ocular manifestations in Fabry\u2019s disease. Arch Ophthalmol 97: 671\u2013676","journal-title":"Arch Ophthalmol"},{"key":"BF03040321_CR7","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38: 769\u2013775","journal-title":"J Med Genet"},{"key":"BF03040321_CR8","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0735-1097(02)02380-X","volume":"40","author":"C Kampmann","year":"2002","unstructured":"Kampmann C, Baehner F, Whybra C, Martin C, Wiethoff CM, Ries M, Gal A, Beck M (2002) Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol 40: 1668\u20131674","journal-title":"J Am Coll Cardiol"},{"key":"BF03040321_CR9","first-page":"157","volume":"81","author":"RJ Desnick","year":"1973","unstructured":"Desnick RJ, Allen KY, Desnick SJ, Raman MK, Bernlohr RW, Krivit W (1973) Fabry\u2019s disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes. J Lab Clin Med 81: 157\u2013171","journal-title":"J Lab Clin Med"},{"key":"BF03040321_CR10","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA, 3rd, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285: 2743\u20132749","journal-title":"JAMA"},{"key":"BF03040321_CR11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ (2001) Safety and efficacy of recombinant human alpha-galactosidase A \u2014 replacement therapy in Fabry\u2019s disease. N Engl J Med 345: 9\u201316","journal-title":"N Engl J Med"},{"key":"BF03040321_CR12","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","volume":"62","author":"BL Thurberg","year":"2002","unstructured":"Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, Desnick RJ, O\u2019Callaghan M (2002) Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62: 1933\u20131946","journal-title":"Kidney Int"},{"key":"BF03040321_CR13","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1136\/bmj.297.6653.872","volume":"297","author":"SH Morgan","year":"1988","unstructured":"Morgan SH, Crawfurd MA (1988) Anderson-Fabry disease. BMJ 297: 872\u2013873","journal-title":"BMJ"},{"key":"BF03040321_CR14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1525-1470.1995.tb00161.x","volume":"12","author":"ED Shelley","year":"1995","unstructured":"Shelley ED, Shelley WB, Kurczynski TW (1995) Painful fingers, heat intolerance, and telangiectases of the ear: easily ignored childhood signs of Fabry disease. Pediatr Dermatol 12: 215\u2013219","journal-title":"Pediatr Dermatol"},{"key":"BF03040321_CR15","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.CIR.0000012626.81324.38","volume":"105","author":"B Sachdev","year":"2002","unstructured":"Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ, Elliott PM (2002) Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 105: 1407\u20131411","journal-title":"Circulation"},{"key":"BF03040321_CR16","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","volume":"81","author":"MH Branton","year":"2002","unstructured":"Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, Goldfarb L, Brady RO, Balow JE, Austin Iii HA, Kopp JB (2002) Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 81: 122\u2013138","journal-title":"Medicine (Baltimore)"},{"key":"BF03040321_CR17","first-page":"112","volume":"25","author":"M Beck","year":"2002","unstructured":"Beck M, Ahlmen J, Cox I, Dehout F, Johannson JO, Garcia de Lorenzo A, MacDermot K, Mehta A, Ricci R, Ries M, Sunder-Plassmann G, Widmer U (2002) Characteristics of patients with Fabry disease in Europe: update from FOS \u2014 Fabry Outcome Survey. J Inherit Metab Dis 25: 112","journal-title":"J Inherit Metab Dis"},{"key":"BF03040321_CR18","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1023\/A:1022833332162","volume":"25","author":"T Kroepfl","year":"2003","unstructured":"Kroepfl T, Paul K, Kotanko P, Plecko B, Paschke E (2003) A novel 6bp insertion in exon 7 associated with an unusual phenotype in a family with Fabry disease. J Inherit Metab Dis 25: 695\u2013696","journal-title":"J Inherit Metab Dis"},{"key":"BF03040321_CR19","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1523-1755.2002.00097.x","volume":"61","author":"R Thadhani","year":"2002","unstructured":"Thadhani R, Wolf M, West ML, Tonelli M, Ruthazer R, Pastores GM, Obrador GT (2002) Patients with Fabry disease on dialysis in the United States. Kidney Int 61: 249\u2013255","journal-title":"Kidney Int"},{"key":"BF03040321_CR20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ndt\/11.supp7.4","volume":"11","author":"D Tsakiris","year":"1996","unstructured":"Tsakiris D, Simpson HK, Jones EH, Briggs JD, Elinder CG, Mendel S, Piccoli G, dos Santos JP, Tognoni G, Vanrenterghem Y, Valderrabano F (1996) Report on management of renale failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry. Nephrol Dial Transplant 11: 4\u201320","journal-title":"Nephrol Dial Transplant"},{"key":"BF03040321_CR21","first-page":"113","volume":"25","author":"M Spada","year":"2002","unstructured":"Spada M, Pagliardini S (2002) Screening for Fabry disease in end-stage nephropathies. J Inherit Metab Dis 25: 113","journal-title":"J Inherit Metab Dis"},{"key":"BF03040321_CR22","first-page":"116","volume":"25","author":"RJ Desnick","year":"2002","unstructured":"Desnick RJ (2002) Fabry disease: unrecognized ESRD and effectiveness of enzyme replacement on renal pathology and function. J Inherit Metab Dis 25: 116","journal-title":"J Inherit Metab Dis"},{"issue":"Suppl 439","key":"BF03040321_CR23","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1651-2227.2002.tb03126.x","volume":"91","author":"AC Hauser","year":"2002","unstructured":"Hauser AC, Lorenz M, Sunder-Plassmann G (2002) The Austrian Screening Programme for Fabry Disease. Acta Paediatr 91 [Suppl 439]: 118","journal-title":"Acta Paediatr"},{"key":"BF03040321_CR24","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1212\/WNL.23.8.871","volume":"23","author":"LA Lockman","year":"1973","unstructured":"Lockman LA, Hunninghake DB, Krivit W, Desnick RJ (1973) Relief of pain of Fabry\u2019s disease by diphenylhydantoin. Neurology 23: 871\u2013875","journal-title":"Neurology"},{"key":"BF03040321_CR25","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1212\/WNL.39.4.598","volume":"39","author":"MR Filling-Katz","year":"1989","unstructured":"Filling-Katz MR, Merrick HF, Fink JK, Miles RB, Sokol J, Barton NW (1989) Carbamazepine in Fabry\u2019s disease: effective analgesia with dose-dependent exacerbation of autonomic dysfunction. Neurology 39: 598\u2013600","journal-title":"Neurology"},{"key":"BF03040321_CR26","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0887-8994(90)90067-B","volume":"6","author":"M Inagaki","year":"1990","unstructured":"Inagaki M, Ohno K, Ohta S, Sakuraba H, Takeshita K (1990) Relief of chronic burning pain in Fabry disease with neurotropin. Pediatr Neurol 6: 211\u2013213","journal-title":"Pediatr Neurol"},{"key":"BF03040321_CR27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ajmg.1320070308","volume":"7","author":"RE Pyeritz","year":"1980","unstructured":"Pyeritz RE, Ullman MD, Moser AB, Braine HG, Moser HW (1980) Plasma exchange removes glycosphingolipid in Fabry disease. Am J Med Genet 7: 301\u2013307","journal-title":"Am J Med Genet"},{"key":"BF03040321_CR28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0006-2944(83)90029-7","volume":"30","author":"E Beutler","year":"1983","unstructured":"Beutler E, Westwood B, Dale GL (1983) The effect of phlebotomy as a treatment of Fabry disease. Biochem Med 30: 363\u2013368","journal-title":"Biochem Med"},{"key":"BF03040321_CR29","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1097\/00007890-200006150-00020","volume":"69","author":"A Ojo","year":"2000","unstructured":"Ojo A, Meier-Kriesche HU, Friedman G, Hanson J, Cibrik D, Leichtman A, Kaplan B (2000) Excellent outcome of renal transplantation in patients with Fabry\u2019s disease. Transplantation 69: 2337\u20132339","journal-title":"Transplantation"},{"key":"BF03040321_CR30","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/00007890-199104000-00004","volume":"51","author":"JF Mosnier","year":"1991","unstructured":"Mosnier JF, Degott C, Bedrossian J, Molas G, Degos F, Pruna A, Potet F (1991) Recurrence of Fabry\u2019s disease in a renal allograft eleven years after successful renal transplantation. Transplantation 51: 759\u2013762","journal-title":"Transplantation"},{"key":"BF03040321_CR31","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/0167-5273(85)90179-2","volume":"7","author":"W Kramer","year":"1985","unstructured":"Kramer W, Thormann J, Mueller K, Frenzel H (1985) Progressive cardiac involvement by Fabry\u2019s disease despite successful renal allotransplantation. Int J Cardiol 7: 72\u201375","journal-title":"Int J Cardiol"},{"key":"BF03040321_CR32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM197307052890103","volume":"289","author":"RO Brady","year":"1973","unstructured":"Brady RO, Tallman JF, Johnson WG, Gal AE, Leahy WR, Quirk JM, Dekaban AS (1973) Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetri-hexosidase in Fabry\u2019s disease. N Engl J Med 289: 9\u201314","journal-title":"N Engl J Med"},{"key":"BF03040321_CR33","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1073\/pnas.76.10.5326","volume":"76","author":"RJ Desnick","year":"1979","unstructured":"Desnick RJ, Dean KJ, Grabowski G, Bishop DF, Sweeley CC (1979) Enzyme therapy in Fabry disease: differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic alpha-galactosidase A isozymes. Proc Natl Acad Sci U S A 76: 5326\u20135330","journal-title":"Proc Natl Acad Sci U S A"},{"key":"BF03040321_CR34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1056\/NEJM200107053450104","volume":"345","author":"A Frustaci","year":"2001","unstructured":"Frustaci A, Chimenti C, Ricci R, Natale L, Russo MA, Pieroni M, Eng CM, Desnick RJ (2001) Improvement in cardiac function in the cardiac variant of Fabry\u2019s disease with galactose-infusion therapy. N Engl J Med 345: 25\u201332","journal-title":"N Engl J Med"},{"key":"BF03040321_CR35","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","volume":"5","author":"JQ Fan","year":"1999","unstructured":"Fan JQ, Ishii S, Asano N, Suzuki Y (1999) Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med 5: 112\u2013115","journal-title":"Nat Med"},{"key":"BF03040321_CR36","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/jgm.214","volume":"3","author":"EJ Estruch","year":"2001","unstructured":"Estruch EJ, Hart SL, Kinnon C, Winchester BG (2001) Non-viral, integrin-mediated gene transfer into fibroblasts from patients with lysosomal storage diseases. J Gene Med 3: 488\u2013497","journal-title":"J Gene Med"},{"key":"BF03040321_CR37","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1089\/10430340252939041","volume":"13","author":"RJ Ziegler","year":"2002","unstructured":"Ziegler RJ, Li C, Cherry M, Zhu Y, Hempel D, van Rooijen N, Ioannou YA, Desnick RJ, Goldberg MA, Yew NS, Cheng SH (2002) Correction of the nonlinear dose response improves the viability of adenoviral vectors for gene therapy of Fabry disease. Hum Gene Ther 13: 935\u2013945","journal-title":"Hum Gene Ther"}],"container-title":["Wiener Klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03040321.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03040321\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03040321","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T08:37:11Z","timestamp":1710319031000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03040321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4]]},"references-count":37,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2003,4]]}},"alternative-id":["BF03040321"],"URL":"https:\/\/doi.org\/10.1007\/bf03040321","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,4]]}}}